H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on United Therapeutics (UTHR – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $218.40.
Fein covers the Healthcare sector, focusing on stocks such as Biogen, AC Immune SA, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -3.9% and a 35.98% success rate on recommended stocks.
In addition to H.C. Wainwright, United Therapeutics also received a Buy from Argus Research’s Jasper Hellweg in a report issued on April 21. However, today, Goldman Sachs maintained a Sell rating on United Therapeutics (NASDAQ: UTHR).
See the top stocks recommended by analysts >>
UTHR market cap is currently $10.11B and has a P/E ratio of 14.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Read More on UTHR:
